Skip to content

QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization

QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00918294
Acronym
QuickOpt
Enrollment
100
Registered
2009-06-11
Start date
2007-09-30
Completion date
2009-09-30
Last updated
2019-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

CRT, heart failure, optimization, Timing cycle optimization methods

Brief summary

QuickOptTM optimization method provides a quicker, simpler and reliable alternative to standard echocardiography methods for optimization of sensed AV, paced AV and V-V delays in patients with CRT-P devices

Interventions

DEVICEQuickOpt

The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.

Sponsors

Abbott Medical Devices
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient meets current CRT-P indications and be implanted with an SJM CRT-P device with V-V timing and a compatible lead system * Patient is able to provide written informed consent for study participation

Exclusion criteria

* Patient has limited intrinsic atrial activity (≤ 40 bpm) * Patient has persistent or permanent AF * Patient has a 2o or 3o heart block * Patient is unable to provide analyzable echocardiogram images * Patient's life expectancy is \<12 months * Patient is \<18 years old * Patient is pregnant * Patient is on IV inotropic agents

Design outcomes

Primary

MeasureTime frame
To compare the aortic velocity time integral value derived by the QuickOptTM optimization method with that derived by the standard echocardiography optimization methods1 day

Secondary

MeasureTime frame
Time required for each optimization method considered in this study1 day
Effects of any spontaneous cardiac events during the QuickOpt optimization process and these events are not limited to premature ventricular complex (PVC), pacemaker-mediated tachycardia (PMT), atrial fibrillation (AF) and far-field R-wave oversensing1 day

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026